keyword
MENU ▼
Read by QxMD icon Read
search

Ceftobiprole

keyword
https://www.readbyqxmd.com/read/29768717/pharmacokinetics-and-target-attainment-of-ceftobiprole-in-asian-and-non-asian-subjects
#1
A E Muller, N Punt, M Engelhardt, A H Schmitt-Hoffmann, J W Mouton
Ceftobiprole is a broad-spectrum cephalosporin. The objective of this study was to test the hypothesis that the pharmacokinetics (PK) and exposure of ceftobiprole in Asian subjects are similar to those in non-Asian subjects. Three approaches were followed. The first compared the individual PK estimates between the 2 subgroups derived from a population PK model previously built. Next, it was determined whether "Asian subject" was a significant covariate. Finally, a pharmacodynamic analysis was performed by comparing measures of exposure and target attainment...
May 16, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29452992/activity-of-ceftobiprole-against-staphylococcus-spec-isolates-derived-from-foreign-body-associated-infections
#2
Gunnar T R Hischebeth, Sascha Gravius, Ernst Molitor, Hendrik Kohlhof, Achim Hoerauf, Caecilia Hilgers, Thomas M Randau
Antibiotic therapy is essential in foreign body associated infections. The treatment regime should aim at high tissue concentrations, high bioavailability, high biofilm penetration and good tolerance. We investigated whether the new cephalosporin ceftobiprole is active against clinical isolates from musculoskeletal foreign body associated infections. One hundred ninety-six staphylococci isolates (coagulase negative staphylococci and Staphylococcus aureus) derived from foreign body associated infections were tested towards susceptibility to ceftobiprole, using a test strip assay and broth microdilution...
January 31, 2018: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29448981/treatment-and-prevention-of-invasive-pneumococcal-disease
#3
A R Domínguez-Alegría, V Pintado, I Barbolla
Invasive pneumococcal disease is a severe infection that mainly affects patients with associated comorbidity. The paediatric conjugate vaccination has resulted in a change in the adult vaccination strategy. The antibiotic resistance of pneumococcus is not currently a severe problem. Nevertheless, the World Health Organisation has included pneumococcus among the bacteria whose treatment requires the introduction of new drugs, such as ceftaroline and ceftobiprole. Although the scientific evidence is still limited, the combination of beta-lactams and macrolides is recommended as empiric therapy for bacteraemic pneumococcal pneumonia...
February 12, 2018: Revista Clínica Española
https://www.readbyqxmd.com/read/29421316/in-vitro-activity-of-novel-anti-mrsa-comparator-agents-against-staphylococci-involved-in-prosthetic-joint-infections
#4
Christophe Isnard, Anne Dhalluin, Damasie Malandain, Quentin Bruey, Michel Auzou, Jocelyn Michon, Jean-Christophe Giard, François Guérin, Vincent Cattoir
OBJECTIVES: Ceftaroline and ceftobiprole are new parenteral cephalosporins with potent activity against methicillin-resistant (MR) staphylococci, which are the leading cause of prosthetic joint infections (PJIs). The aim of the study was to determine and compare in vitro activities of both molecules against staphylococcal isolates recovered from clinically-documented PJIs. METHODS: A collection of 200 non-redundant clinical isolates (100 Staphylococcus aureus and 100 coagulase-negative staphylococci [CoNS], including 19 and 27 MR isolates, respectively) was studied...
February 5, 2018: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/29395713/antimicrobial-activity-of-ceftobiprole-and-comparator-agents-when-tested-against-contemporary-gram-positive-and-negative-organisms-collected-from-europe-2015
#5
M A Pfaller, R K Flamm, L R Duncan, J M Streit, M Castanheira, H S Sader
Susceptibility testing of ceftobiprole and comparators against 12,240 isolates was performed following CLSI/EUCAST guidelines. The percentage of susceptible MRSA isolates was higher for ceftobiprole (96.5% susceptible) than for ceftaroline (86.2% susceptible). Both ceftobiprole (MIC50/90 , 0.5/2 mg/L) and ceftaroline (MIC50/90 , 0.25/1 mg/L) demonstrated potent activity against coagulase-negative staphylococci. Ceftobiprole demonstrated good potency against Enterococcus faecalis (MIC50/90 values of 0.5/2 mg/L); ceftaroline (MIC50/90 , 2/8 mg/L) was 4-fold less active against these strains...
May 2018: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/28755095/neurological-adverse-effects-attributable-to-%C3%AE-lactam-antibiotics-a-literature-review
#6
REVIEW
Samuel Deshayes, Antoine Coquerel, Renaud Verdon
β-lactam antibiotics are commonly prescribed antibiotic drugs. To describe the clinical characteristics, risk markers and outcomes of β-lactam antibiotic-induced neurological adverse effects, we performed a general literature review to provide updated clinical data about the most used β-lactam antibiotics. For selected drugs in each class available in France (ticarcillin, piperacillin, temocillin, ceftazidime, cefepime, cefpirome, ceftaroline, ceftobiprole, ceftolozane, ertapenem and aztreonam), a systematic literature review was performed up to April 2016 via an electronic search on PubMed...
December 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/28732783/future-trends-in-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-infection-an-in-depth-review-of-newer-antibiotics-active-against-an-enduring-pathogen
#7
REVIEW
A M Bal, M Z David, J Garau, T Gottlieb, T Mazzei, F Scaglione, P Tattevin, I M Gould
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009...
September 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28666751/recently-approved-antibacterials-for-methicillin-resistant-staphylococcus-aureus-mrsa-and-other-gram-positive-pathogens-the-shock-of-the-new
#8
REVIEW
Michael Z David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M Gould
A number of novel antimicrobial drugs with activity against Gram-positive bacterial pathogens have been licensed in the past 4 years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci and other antibiotic-resistant Gram-positive pathogens. The advantages and disadvantages of these drugs are not yet fully appreciated. Here we review the five most promising newly approved compounds, namely ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid...
September 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28642145/new-and-improved-a-review-of-novel-antibiotics-for-gram-positive-bacteria
#9
REVIEW
M Abbas, M Paul, A Huttner
BACKGROUND: The number of antibiotics in the pipeline targeting Gram-positive pathogens has increased in recent years. AIMS: This narrative review aims to provide a summary of existing evidence on efficacy, microbiological spectrum and safety of novel systemic antibiotics that have either recently been licensed or completed phase III trials, and possess activity predominantly against Gram-positive organisms. SOURCES: A review of the published literature via the MEDLINE database was performed...
October 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28598693/managing-community-acquired-pneumonia-in-the-elderly-the-next-generation-of-pharmacotherapy-on-the-horizon
#10
REVIEW
B Amalakuhan, K L Echevarria, M I Restrepo
Community acquired pneumonia (CAP) is associated with high rates of morbidity and mortality, especially among the elderly. Antibiotic treatment for CAP in the elderly is particularly challenging for many reasons, including compliance issues, immunosuppression, polypharmacy and antimicrobial resistance. There are few available antibiotics that are able to address these concerns. Areas covered: After a systematic review of the current literature, we describe seven novel antibiotics that are currently in advanced stages of development (phase 3 and beyond) and show promise for the treatment of CAP in those over the age of 65...
August 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28577932/in-vitro-activity-of-several-antimicrobial-agents-against-methicillin-resistant-staphylococcus-aureus-mrsa-isolates-expressing-aminoglycoside-modifying-enzymes-potency-of-plazomicin-alone-and-in-combination-with-other-agents
#11
María Carmen López Díaz, Esther Ríos, Iciar Rodríguez-Avial, Rosa Janneth Simaluiza, Juan José Picazo, Esther Culebras
This study investigated the in-vitro activity of clinically relevant aminoglycosides and new antimicrobial agents-plazomicin, ceftobiprole and dalbavancin-against 55 methicillin-resistant Staphylococcus aureus (MRSA) isolates producing aminoglycoside-modifying enzymes (AMEs). The checkerboard method was used to assess synergism between plazomicin and four antibiotics (fosfomycin, ceftobiprole, cefoxitin and meropenem), and time-kill assays were performed for the most active combinations. Among the aminoglycosides tested, plazomicin was the most active agent against MRSA, with >90% of isolates being inhibited at a minimum inhibitory concentration (MIC) of ≤1 mg/L...
August 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28373193/high-level-resistance-of-staphylococcus-aureus-to-%C3%AE-lactam-antibiotics-mediated-by-penicillin-binding-protein-4-pbp4
#12
Stephanie M Hamilton, J Andrew N Alexander, Eun Ju Choo, Li Basuino, Thaina M da Costa, Anatoly Severin, Marilyn Chung, Sandra Aedo, Natalie C J Strynadka, Alexander Tomasz, Som S Chatterjee, Henry F Chambers
Penicillin-binding protein 4 (PBP4), a nonessential, low-molecular-weight penicillin-binding protein of Staphylococcus aureus , has been implicated in low-level resistance to β-lactam antibiotics, although the mechanism is unknown. Mutations in PBP4 and its promoter were identified in a laboratory-generated mutant strain, CRB, which expresses high-level resistance to β-lactams, including resistance to the new-generation cephalosporins active against methicillin-resistant strains of S. aureus These mutations did not appreciably alter the β-lactam antibiotic binding affinity of purified recombinant mutant PBP4 compared to that of wild-type PBP4...
June 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28338911/new-horizons-in-hospital-acquired-pneumonia-in-older-people
#13
Victoria Ewan, Thomas Hellyer, Julia Newton, John Simpson
Approximately 1.5% of hospital patients develop hospital acquired pneumonia. Aspiration is the major risk factor for pneumonia and is associated with reduced ability to mechanically clear respiratory pathogens into the stomach. Currently non-invasive methods of diagnosing hospital acquired pneumonia are less robust than invasive methods, and lead to over-diagnosis. Accurate diagnosis is key to surveillance, prevention and treatment of HAP, and also to improving outcomes; newer imaging modalities such as phase contrast X-ray imaging and nanoparticle enhanced magnetic resonance imaging may help...
May 1, 2017: Age and Ageing
https://www.readbyqxmd.com/read/28325540/corrigendum-to-rates-of-susceptibility-of-carbapenems-ceftobiprole-and-colistin-against-clinically-important-bacteria-collected-from-intensive-care-units-in-2007-results-from-the-surveillance-of-multicenter-antimicrobial-resistance-in-taiwan-smart-j-microbiol
#14
Shio-Shin Jean, Wen-Sen Lee, Kwok-Woon Yu, Chun-Hsing Liao, Chin-Wan Hsu, Feng-Yi Chang, Wen-Chien Ko, Ray-Jade Chen, Jiunn-Jong Wu, Yen-Hsu Chen, Yao-Shen Chen, Jien-Wei Liu, Min-Chi Lu, Carlos Lam, Cheng-Yi Liu, Po-Ren Hsueh
No abstract text is available yet for this article.
March 16, 2017: Journal of Microbiology, Immunology, and Infection, Wei Mian Yu Gan Ran za Zhi
https://www.readbyqxmd.com/read/28314920/-new-antibiotics-standstill-or-progress
#15
J Rademacher, T Welte
The development of resistance to antibiotics has been ignored for a long time. But nowadays, increasing resistance is an important topic. For a decade no new antibiotics had been developed and it is not possible to quickly close this gap of new resistance and no new drugs. This work presents six new antibiotics (ceftaroline, ceftobiprole, solithromycin, tedizolid, ceftolozane/tazobactam, ceftazidime/avibactam). In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA...
April 2017: Medizinische Klinik, Intensivmedizin und Notfallmedizin
https://www.readbyqxmd.com/read/28264613/pharmacokinetic-drug-evaluation-of-ceftobiprole-for-the-treatment-of-mrsa
#16
REVIEW
Karolyn S Horn, Larry H Danziger, Keith A Rodvold, Robert C Glowacki
Methicillin-resistant Staphylococcus aureus (MRSA), while decreasing in overall incidence, is still a prominent concern world-wide. New agents coming to market in the last 10 years allow practitioners to optimize treatment for MRSA infections. Ceftobiprole is a cephalosporin agent with MRSA activity, currently approved in selected countries for the treatment of community-acquired pneumonia and hospital-acquired pneumonia. Areas covered: Relevant literature regarding spectrum of activity, pharmacokinetics, pharmacodynamics, and clinical trials will be discussed...
April 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28134677/are-there-any-reasons-to-change-our-behavior-in-necrotizing-fasciitis-with-the-advent-of-new-antibiotics
#17
REVIEW
Francesco Menichetti, Simone Giuliano, Simona Fortunato
PURPOSE OF REVIEW: The treatment of necrotizing fasciitis requires a multifaceted approach, consisting of surgical source control with immediate surgical debridement along with life support, clinical monitoring, and antimicrobial therapy. Many drugs are now available for the treatment of this life-threatening infectious disease, and the purpose of this review is to provide the reader with an updated overview of the newest therapeutic options. RECENT FINDINGS: Because most necrotizing soft tissue infections are polymicrobial, broad-spectrum coverage is advisable...
April 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/27889013/methicillin-resistant-staphylococcus-aureus-infections-a-review-of-the-currently-available-treatment-options
#18
REVIEW
S M Purrello, J Garau, E Giamarellos, T Mazzei, F Pea, A Soriano, S Stefani
This review is the result of discussions that took place at the 5th MRSA Working Group Consensus Meeting and explores the possible treatment options available for different types of infections due to methicillin-resistant Staphylococcus aureus (MRSA), focusing on those antibiotics that could represent a valid alternative to vancomycin. In fact, whilst vancomycin remains a viable option, its therapy is moving towards individualised dosing. Other drugs, such as the new lipoglycopeptides (oritavancin, dalbavancin and telavancin) and fifth-generation cephalosporins (ceftaroline and ceftobiprole), are showing good in vitro potency and in vivo efficacy, especially for patients infected with micro-organisms with higher vancomycin minimum inhibitory concentrations (MICs)...
December 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27856079/in-vitro-activity-of-ceftobiprole-on-440-staphylococcus-aureus-strains-isolated-from-bronchopulmonary-infections
#19
E Hodille, L Delouere, C Bouveyron, H Meugnier, M Bes, A Tristan, F Laurent, F Vandenesch, G Lina, O Dumitrescu
OBJECTIVE: We assessed the in vitro activity of ceftobiprole on 440 Staphylococcus aureus clinical strains isolated from bronchopulmonary infections (2010-2014). METHODS: S. aureus isolates were characterized for methicillin resistance, PVL status, and clonal complex. All isolates were tested for minimal inhibitory concentrations (MIC) determination by broth microdilution method for ceftobiprole, ceftaroline fosamil, and comparator antibiotics (linezolid, tigecycline, vancomycin, and daptomycin)...
November 14, 2016: Médecine et Maladies Infectieuses
https://www.readbyqxmd.com/read/27690689/ceftobiprole-medocaril-bal-5788-for-the-treatment-of-complicated-skin-infections
#20
Amelia Deitchman, Daniel de Jong, April Barbour, Hartmut Derendorf
With resistance of S. aureus, the most prevalent identified pathogen in skin and soft tissue infections, on the rise, the need for safe, effective, and well-tolerated antibiotics is crucial. Ceftobiprole medocaril (BAL-5788), ceftobiprole's parenteral prodrug, is a bactericidal cephalosporin with broad Gram-positive and Gram-negative activity that has shown to be well-tolerated and noninferior to vancomycin and vancomycin plus ceftazidime in the treatment of MRSA complicated skin and skin structure infections (cSSSIs) in clinical trials...
October 2, 2016: Expert Review of Anti-infective Therapy
keyword
keyword
56653
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"